Introduction to Drug Class of CDK4/6 Inhibitors in Breast Cancer

Dr. Carlos Barrios discusses the use of CDK46 inhibitors in the management of breast cancer, highlighting a specific case study and the effectiveness of these inhibitors in improving patient outcomes.

Target Audience

Healthcare Professionals

Learning Objectives

  • Identify and interpret factors that influence breast cancer risk, including genetic markers, tumor grade, and lymph node involvement.
  • Apply risk assessment tools and models to categorize patients into high, medium, or low risk in clinical practice.
  • Recognize the different risk profiles of patients with EBC.
  • Understand the prognostic and predictive value of clinical-pathological factors and risk evaluation tools.

This activity is supported by an educational grant from Eli Lilly.

Course summary

Course opens: 
09/08/2026
Course expires: 
09/30/2031
Cost:
$0.00
Rating: 
0
Dr. Carlos Barrios

Dr. Carlos Barrios

Director and Principal Investigator of the Oncology Research Center at Hospital São Lucas, PUCRS
Director of LACOG (Grupo Latino Americano de Investigación Clínica en Oncologia – Latin American Clinical Oncology Research Group)
Oncologist of the Oncoclínicas Group in Porto Alegre

Price

Cost:
$0.00
Please login or register to take this course.